

July 19, 2013



## **Mentor Capital Cancer Immunotherapy Index Gains 31% During First Half of 2013**

SAN DIEGO--(BUSINESS WIRE)-- Mentor Capital, Inc. (Pink Sheets:MNTR) reports that its proprietary Cancer Immunotherapy Index appreciated 30.6% during the first half of 2013. The equally weighted Cancer Immunotherapy Index is regularly benchmarked against the appreciation of the average of the NASDAQ, S&P, and NYSE Biotech Indices. For the first half the biotech indices averaged a 34.5% gain.

Galena (45%), Inovio (59%) and Celldex (133%) have led the sector in gains during the January through June 2013 period. Dendreon (\$650 Million), Celldex (\$1,262 Million) and NewLink Genetics (\$392 Million) represent 66% of the market capitalization of the fifteen member Cancer Immunotherapy Index which has a combined total share value of \$3.5 Billion.

The Mentor Capital Cancer Immunotherapy Index companies and their performance for the first twenty-six weeks of 2013 follow: Galena Biopharma Corporation (NASDAQ:GALE) +45.10%, NewLink Genetics Corporation (NASDAQ:NLNK) +22.40%, Vical Incorporated (NASDAQ:VICL) +7.56%, Inovio Pharmaceuticals, Inc. (NYSEMKT:INO) +59.36%, Dendreon (NASDAQ:DNDN) -22.12%, Immunocellular Therapeutics, Ltd. (NYSE MKT:IMUC) +1.04%, Agenus (NASDAQ:AGEN) -7.56%, Oncothyreon (NASDAQ:ONTY) -18.23%, Biovest International (OTCMKTS:BVTIQ) -84.80%, Celldex Therapeutics (NASDAQ:CLDX) +132.64%, Northwest Biotherapeutics (NASDAQ:NWBO) +7.07%, CEL – SCI Corp. (NYSEMKT:CVM) -21.11% , Generex Biotechnology (OTCBB:GNBT) +32.00% as a proxy for its wholly-owned immunotherapeutic subsidiary, Antigen Express, Provectus Pharmaceuticals, Inc. (OTCMKTS:PVCT) +14.29% and Advaxis, Inc. (OTCBB:ADXSD) +34.67% - all for an average 2013 YTD gain of +30.60%. (Annualized rate: +61.20%).

Mentor Capital, Inc., by acquisition or stock purchase, seeks to invest in leading-edge private and public cancer companies, and certain other situations. Mentor created the Cancer Immunotherapy Index July 10, 2009. Since then, it has invested or maintained a tracking position in all companies in the Cancer Immunotherapy Index which can be found at [www.MentorCapital.com](http://www.MentorCapital.com).

**Forward Looking Statements, Safe Harbor and Risk Descriptions are Incorporated by Reference from the MNTR Company Web Site above.**

Mentor Capital, Inc.  
Chester Billingsley, CEO  
(760) 788-4700

Source: Mentor Capital, Inc.